1. Prevalence and prognosis of autoimmune liver disease in a population based childhood-onset IBD cohort.
Petter Malmborg, Maja Ideström, Jan Björk, Annika Bergquist, Henrik Arnell, Björn Fischler, Eva Beijer, Antal Nemeth, Hans Hildebrand, Thomas Casswall

2. Switching from Remicade® to Remsima® is safe and feasible: a prospective, open-label study.
Lydia C.T. Buer, Bjørn A. Moum, Milada Cvancarova, David J. Warren, Asle W. Medhus, Marte L. Høivik

3. Restorative proctocolectomy in a well established setting – few complications with good functional outcome.
Marie Louise Sunde, Tom Øresland, Arne E. Færden

4. Faecal calprotectin is a useful marker of mucosal healing after treatment for active ulcerative colitis.
Vendel Kristensen, Arne Røseth, Tahir Ahmad, Viggo Skar, Bjørn Moum

5. Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab test.
Ida Sjøstrøm, Gunn Helen Malmstrøm, Arne Røseth

6. Geographic variations in the use of biologics among patients with IBD: A Norwegian Registry study.
Sandre Svatun Lirhus, Hans Olav Melberg, Marte Lie Høivik, Bjørn Moum

7. Biosimilar infliximab is not inferior to originator infliximab: Results from the 52-week randomized NOR-SWITCH trial.
Kristin K Jørgensen, Inge C Olsen, Guro L Goll, Merete Lorentzen, Nils Bolstad, Espen A Haavardsholm, Knut EA Lundin, Cato Mørk Professor, Tore K Kvien, Jørgen Jahnsen on behalf of the Nor-Switch study group

8. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.
Erik Andersson, Daniel Bergemalm, Robert Kruse, Gunter Neumann, Mauro D’Amato, Dirk Repsilber, Jonas Halfvarson

9. Clinical implications of assay specific differences in f-Calprotectin when monitoring IBD activity over time.
Karin Amcoff, Mats Stridsberg, Maria Lampinen, Anders Magnuson, Marie Carlson, Jonas Halfvarson

10. Intestinal dysbiosis in collagenous colitis.
Carstens A, Dicksved J, Nelson R, Andréasson A, Bohr J, Tysk C, Agréus L, Engstrand L, Halfvarson J

11. Phenotype correlation in inflammatory bowel disease compared to serologic-antibody activity at diagnosis and after treatment.
Trond Espen Detlie, Milada Cvancarova Smastuen, Petr Ricanek, Stephan Brackmann, Andreas Rydning, Morten Harald Vatn, Jørgen Jahnsen

12. Rapid faecal calprotectin test and symptom index for monitoring the disease activity in colonic IBD.
Anna-Maija Puolanne, Kaija-Leena Kolho, Martti Färkkilä